Atria Investments Inc Has $30.79 Million Stake in Eli Lilly and Company $LLY

Atria Investments Inc reduced its stake in Eli Lilly and Company (NYSE:LLY) by 13.2% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 40,355 shares of the company’s stock after selling 6,162 shares during the period. Atria Investments Inc’s holdings in Eli Lilly and Company were worth $30,791,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Sumitomo Mitsui Financial Group Inc. bought a new position in shares of Eli Lilly and Company in the 2nd quarter valued at $27,000. Evolution Wealth Management Inc. acquired a new position in Eli Lilly and Company in the 2nd quarter worth about $29,000. Steph & Co. raised its position in Eli Lilly and Company by 290.0% in the third quarter. Steph & Co. now owns 39 shares of the company’s stock valued at $30,000 after purchasing an additional 29 shares during the last quarter. Financial Gravity Companies Inc. acquired a new stake in shares of Eli Lilly and Company during the second quarter valued at about $31,000. Finally, Bare Financial Services Inc grew its holdings in shares of Eli Lilly and Company by 263.6% during the second quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock worth $31,000 after purchasing an additional 29 shares during the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $1,015.48 on Thursday. The firm has a 50 day moving average of $1,051.24 and a 200-day moving average of $903.76. The company has a market cap of $960.02 billion, a price-to-earnings ratio of 44.25, a price-to-earnings-growth ratio of 0.94 and a beta of 0.39. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 112.50%. The business had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. During the same period in the prior year, the firm earned $5.32 earnings per share. Eli Lilly and Company’s revenue was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, equities analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be issued a dividend of $1.73 per share. The ex-dividend date is Friday, February 13th. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 annualized dividend and a yield of 0.7%. Eli Lilly and Company’s dividend payout ratio is currently 26.14%.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on LLY. TD Cowen raised their price objective on shares of Eli Lilly and Company from $960.00 to $1,250.00 and gave the company a “buy” rating in a report on Thursday, January 29th. CICC Research raised their price target on shares of Eli Lilly and Company from $801.00 to $1,060.00 and gave the company a “neutral” rating in a research note on Thursday, November 13th. Wells Fargo & Company lifted their price target on shares of Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the stock an “overweight” rating in a report on Thursday, February 5th. Truist Financial set a $1,281.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, February 5th. Finally, Daiwa Securities Group set a $1,230.00 target price on Eli Lilly and Company and gave the stock a “buy” rating in a research report on Tuesday, December 16th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $1,217.71.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly agreed to acquire Orna Therapeutics for up to $2.4 billion, adding circular‑RNA and in‑vivo CAR‑T capabilities to diversify beyond GLP‑1s and bolster its next‑gen RNA/cell therapy pipeline. Read More.
• Positive Sentiment: Lilly advanced obesity and cardiometabolic candidates: eloralintide moved into Phase 3 (expanding its obesity franchise) and solbinsiran showed Phase 2 progress in high‑risk cholesterol — both increase future revenue optionality. Read More. Read More.
• Positive Sentiment: Strong fundamentals: 2025 results and management guidance underpin upside (large revenue/EPS jumps and 2026 guidance lifted), supporting long‑term earnings growth expectations. Read More.
• Positive Sentiment: Institutional buying: Fisher Asset Management increased its stake, signaling confidence from a major investor. Read More.
• Neutral Sentiment: Lilly inked a partnership with gene‑editing start‑up Seamless Therapeutics to broaden R&D approaches — potential upside, but early and dilutive timelines make near‑term impact uncertain. Read More.
• Neutral Sentiment: Multiple bullish commentaries and buy‑thesis pieces highlight secular GLP‑1 leadership and pipeline depth — helpful for sentiment but not new fundamental data. Read More. Read More.
• Negative Sentiment: Valuation and momentum risk: after a >60% six‑month rally and a high multiple, investors may be booking gains; stretched valuation raises sensitivity to any slowdown in GLP‑1 adoption or clinical setbacks. Read More.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.